PGNY

Over the past six months (approximately March-September 2026), Progyny's stock experienced volatility. In Q1 2026, the company reported record revenue of $328.5 million, high member engagement, and announced a share repurchase program. In Q2 2026, sales rose 5% (or 11% excluding a client departure) and adjusted EPS jumped 15%, surpassing Wall Street expectations; however, cautious Q3 guidance led to a 6% stock drop, though full-year revenue guidance was reiterated. There has been continued insider selling activity, including a director exercising options and selling shares, and the CEO and CFO having shares withheld for taxes. Analysts maintain a 'Moderate Buy' consensus with an average price target of $34.36, with several firms reiterating or raising their price targets. Progyny also secured CalPERS as a new fertility benefits client starting July 2027, but its shares have been impacted by broader healthcare sector weakness and a 'risk-off' market tone.